Mark A. Rubin
23Patents
6h-index
29Co-inventors
65Inventor score
Filing activity: Aug 1, 2002 → Apr 12, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7229774B2 | Expression profile of prostate cancer | Emerging Cross-Sectional Technologies | 56 | Expired |
| US7981609B2 | Methods for identifying and using SNP panels | Physics | 54 | Active |
| US7718369B2 | Recurrent gene fusions in prostate cancer | Emerging Cross-Sectional Technologies | 36 | Active |
| US7332290B2 | Dectection of AMACR cancer markers in urine | Emerging Cross-Sectional Technologies | 20 | Expired |
| US8211645B2 | Recurrent gene fusions in prostate cancer | Emerging Cross-Sectional Technologies | 7 | Active |
| US7666595B2 | Biomarkers for predicting prostate cancer progression | Physics | 7 | Active |
| US8580509B2 | Recurrent gene fusions in prostate cancer | Emerging Cross-Sectional Technologies | 5 | Active |
| US7767393B2 | Expression profile of prostate cancer | Emerging Cross-Sectional Technologies | 4 | Active |
| US9745635B2 | Recurrent gene fusions in prostate cancer | Emerging Cross-Sectional Technologies | 3 | Active |
| US8106037B2 | Identification and treatment of estrogen responsive prostate tumors | Chemistry; Metallurgy | 3 | Active |
| US9284609B2 | Recurrent gene fusions in prostate cancer | Emerging Cross-Sectional Technologies | 2 | Active |
| US9866513B2 | Systems and methods to control the lifetime of online posts | Electricity | 2 | Active |
| US10190173B2 | Recurrent gene fusions in prostate cancer | Emerging Cross-Sectional Technologies | 2 | Active |
| US8969527B2 | Recurrent gene fusions in prostate cancer | Emerging Cross-Sectional Technologies | 1 | Active |
| US9090899B2 | Methods of diagnosing and treating prostate cancer characterized by NDRG1-ERG fusion | Human Necessities | 1 | Active |
| US7803552B2 | Biomarkers for predicting prostate cancer progression | Physics | 1 | Active |
| US9951388B2 | Spectral imaging for measurement of nuclear pathology features in cancer cells prepared for in situ analysis | Emerging Cross-Sectional Technologies | 1 | Active |
| US10294476B2 | NEAT1 as a prognostic marker and therapeutic target for prostate cancer | Chemistry; Metallurgy | 0 | Active |
| US11441189B2 | Image acquisition methods for simultaneously detecting genetic rearrangement and nuclear morphology | Emerging Cross-Sectional Technologies | 0 | Active |
| US9458213B2 | Compositions and methods for diagnosing prostate cancer based on detection of SLC45A3-ELK4 fusion transcript | Chemistry; Metallurgy | 0 | Active |
| US9678077B2 | ERG/TFF3/HMWCK triple immunostain for detection of prostate cancer | Physics | 0 | Active |
| US10443102B2 | Recurrent SPOP mutations in prostate cancer | Chemistry; Metallurgy | 0 | Active |
| US9568483B2 | Molecular subtyping, prognosis and treatment of prostate cancer | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.